Previous Close | 0.9209 |
Open | 0.8500 |
Bid | 0.8212 x 200 |
Ask | 0.8322 x 400 |
Day's Range | 0.8110 - 0.8700 |
52 Week Range | 0.6500 - 1.4900 |
Volume | |
Avg. Volume | 1,530,503 |
Market Cap | 336.857M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Amarin (AMRN) posts better-than-expected first-quarter 2024 results. Vascepa's sales in the United States continue to be hurt by generic competition.
Revenue Declines Amidst Generic Competition, Yet Strategic Initiatives Show Promise
Amarin (AMRN) secures a new patent for Vazkepa in Europe, which extends its exclusivity for eight more years. It achieves success in defending another patent on the drug against third parties.